🇺🇸 KETOPROFEN LYSINE in United States

167 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 167

Most-reported reactions

1. Drug Abuse — 43 reports (25.75%)
2. Vomiting — 20 reports (11.98%)
3. Abdominal Pain Upper — 14 reports (8.38%)
4. Suicide Attempt — 14 reports (8.38%)
5. Urticaria — 14 reports (8.38%)
6. Drug Hypersensitivity — 13 reports (7.78%)
7. Loss Of Consciousness — 13 reports (7.78%)
8. Dizziness — 12 reports (7.19%)
9. Nausea — 12 reports (7.19%)
10. Tachycardia — 12 reports (7.19%)

Source database →

Frequently asked questions

Is KETOPROFEN LYSINE approved in United States?

KETOPROFEN LYSINE does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for KETOPROFEN LYSINE in United States?

Marketing authorisation holder not available in our data.